| Project/Area Number |
15K15090
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 14-3-3 / 細胞外分泌 / 分泌経路 / 14-3-3 sigma / 非定型的細胞外分泌 / CLSP |
|---|
| Outline of Final Research Achievements |
To elucidate the mechanism underlying the secretion of 14-3-3sigma, a series of experiments have been performed and the following results have been obtained.First, the analysis using various deletion mutants of 14-3-3sigma indicate that the N-terminal 82 amino acids region is important for its binding to CLSP. Treatment with brefendin results in the almost complete defect of 14-3-3sigma secretion. This result indicates that 14-3-3sigma is secreted via the so-called unconventional secretion pathway. Third, an secretion assay system has been established by which 14-3-3sigma, C-terminally tagged with Nanoluc, is overexpressed in cultured cells. Using this assay, the involvement of Grasp1 and Grasp2 in the secretion of 14-3-3sigma has been addressed. Until now, consistent results have not been obtained by the gain-of-function experiments or the loss-of-function experiments. Finally, no 14-3-3sigma-binding proteins other than CLSP have been identified.
|
